Abstract 237P
Background
Advanced urothelial cancer is an aggressive tumor type with high propensity of recurrence even after adequate surgical resection. The CheckMate-274 trial heralded a new era for resected urothelial cancer by the addition of adjuvant nivolumab which significantly reduced recurrence rate and prolonged survival. In the CheckMate-274 trial, 21% of the patients were upper urinary tract cancers (UTUC, including renal pelvis, collecting duct, ureter), reflecting the prevalence of UTUC in the western population. Asian patients have a significantly higher proportion of UTUC compared to western countries. Furthermore, in Asia, especially Taiwan, the etiology of urothelial cancers is likely distinct from western countries, with environmental factors as a main contributing factor. Therefore, the clinical efficacy of nivolumab in resected UTUC is relatively underinvestigated and warrants more research.
Methods
We retrospectively analyzed patients with resected urothelial cancer at the Taipei Veterans General Hospital, Taiwan, who received adjuvant nivolumab following adequate surgical resection. Clinical and pathological information were gathered and analyzed. We further collected genomic and clinical data for a further analysis of patients who had recurrence after completing adjuvant nivolumab.
Results
Our cohort included a total of 22 patients. 14 were female, 8 were male patients. 2 patients had bladder cancer, 4 patients had cancer of the ureter, and 16 patients had cancer of the renal pelvis (total of 20 UTUC). 3 patients were stage 2, 11 patients were stage 3, 8 patients were stage 4. With a median follow up time of 422.5 days, 7 patients had recurrence. In all 7 patients with recurrence, the median time to recurrence was 224 days (7.47 months). In the overall cohort, DFS was still not reached since the majority of patients were still in remission. We further performed genetic and pathological analysis for patients with recurrence.
Conclusions
Urothelial cancer is an aggressive disease with a dismal outcome. Adjuvant nivolumab significantly improved outcomes, but a portion of patients still present with rapid recurrence. Our study highlights the aggressiveness of UTUC which is highly prevalent in Asian countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract